Home › Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A
 

Keywords :   


Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A

2013-07-02 19:26:33| Chemicals - Topix.net

Onyx Pharmaceuticals Inc., which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.

Tags: real ma premium deal

Category:Chemicals

Latest from this category

All news
12.11Benjamin Moore Expands Partnership with Roadie to Accelerate Paint Delivery for DIYers and Pros
11.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
11.11Protech Group Acquires Caldwell Chemical Coatings
11.11Asian Paints Reports 2Q 2024-25 Fiscal Results
10.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
Chemicals »
24.111000 15
24.11 nike soccer usa national team uniform
24.1160266
24.11 1
24.11
24.11GREATEST HITS ALTER EGO EGOIST
24.11(ALINCO)
24.11[]34
More »